| Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. | |
MedLine Citation:
|
PMID: 19843052 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The new paediatric European Union (EU) regulation and the consequent demand for paediatric studies on one hand and the ethical need for minimizing the burden of studies in children on the other hand necessitate optimal techniques in the assessment of safety/efficacy and use of drugs in children. Modelling and simulation (M&S) is one way to circumvent some difficulties in developing medicinal products in children. M&S allows the quantitative use of sparse sampling, characterization and prediction of pharmacokinetics/pharmacodynamics (PK/PD), extrapolation from adults to children, interpolation between paediatric age subsets, optimal use of scientific literature and in vitro/preclinical data. Together, industry, academia and regulators recognize the usefulness of modelling and simulation in this setting. However, even if M&S is an emerging science, its integration in the EU regulatory decision making is for the time being deficient and M&S expertise is concentrated in big pharmaceutical companies and academic institutions. The European Medicines Agency, acknowledging all the above conditions, organized and hosted a Workshop on Modelling in Paediatric Medicines. The article presents the personal views of the authors on the issues presented and discussed in the workshop.We attempt to identify the regulatory framework for the use of M&S in paediatric medicinal development and to make proposals for model-based paediatric medicinal development. The objective is to open the discussion between industry, academia, paediatricians and regulators on the optimal use of M&S in paediatric medicinal development. |
Authors:
|
Efthymios Manolis; Gérard Pons |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 68 ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 493-501 Citation Subset: IM |
Affiliation:
|
Scientific Advice and Orphan Drugs, European Medicines Agency, London, UK. efthymios.manolis@emea.europa.eu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Progenitors in motion: mechanisms of mobilization of endothelial progenitor cells.
Next Document: Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin ...